| | |
|---|
| ASPsiRNA information |
siRNA Id: | aspsirna0853
|
|
siRNA Name: | ShKras (G12D) 2
|
| Mismatch information |
Wild siRNA (As strand 3'->5'): | GCCGCCGCCGUCTCCGCCG
|
|
ASP-siRNA (As strand 3'->5'): | GUCGCCGCCGUCTCCGCCG
|
|
Mismatch position in siRNA: | U18C |
| Gene Information |
Gene Name | K-RAS (KRAS) |
|
Target Sequence (5'->3'): | CGGCGGCGGCAGTGGCGGCGGCGAA
|
|
Wild allele (5'->3'): | CGGCGGCGGCAGTGGCGGC
|
|
Mutant allele (5'->3'): | CAGCGGCGGCAGTGGCGGC
|
|
Position of siRNA on target gene: | 35-53
|
| Respective Gene/Protein Resources |
GenBank Accession: | NM_033360.3 |
| Cytogenic location: | 12p12.1 |
| Chromosomal coordinates: | 12:25,358,179-25,403,869 |
| UniProt ID: | P01116 |
| HUGO ID: | 6407 |
|
Reference SNp(RefSNP): | rs12191352 |
| Disease/Mutation information |
Target Mutation: | c.36G>A,p.Gly12Asp
|
|
Matation type/variant: | Single nucleotide variant/Missense variant
|
|
Mutation at gene level: | NG_007524.1:g.10571G>A
|
|
Pathogenic status of mutation: | Pathogenic
|
|
Disease: | Pancreatic cancer |
| Clinical Resources |
ClinVar ID: | 12582 |
|
KEGG disease ID: | H00019 |
|
OMIM ID: | 260350 |
|
COSMIC: | KRAS |
|
DECIPHER: | KRAS |
|
GeneTests: | KRAS |
| ASP siRNA details |
Mutant allele (5'->3'): | CAGCGGCGGCAGTGGCGGC
|
|
ASP-siRNA (As strand 3'->5'): | GUCGCCGCCGUCTCCGCCG
|
|
Percentage efficacy of ASP-siRNA for mutant allele: | 70
|
|
Wild allele (5'->3'): | CGGCGGCGGCAGTGGCGGC
|
|
ASP-siRNA (As strand 3'->5'): | GUCGCCGCCGUCTCCGCCG
|
|
Percentage efficacy of ASP-siRNA for wild allele: | 40
|
|
Relative difference: | 30
|
| Wild siRNA details |
Wild allele (5'->3'): | CGGCGGCGGCAGTGGCGGC
|
|
Wild siRNA (As strand 3'->5'): | GCCGCCGCCGUCTCCGCCG
|
|
Percentage efficacy of wild siRNA for wild allele: | NA
|
|
Wild allele (5'->3'): | CGGCGGCGGCAGTGGCGGC
|
|
ASP-siRNA (As strand 3'->5'): | GUCGCCGCCGUCTCCGCCG
|
|
Percentage efficacy of Wild sirna for mutant allele: | NA
|
|
Relative difference : | NA
|
| General information |
Mismatch incorporated in siRNA/Target: | siRNA
|
| Cell-line used: | CD18/HPAF |
| Experimental technique used: | Western blot |
| Transfection method: | Lipofectamine 2000 |
| siRNA expression method: | Invitrogen |
| Post-transfection duration: | 48 hours |
| Concentration used: | 10ml |
| Reference: | 21364589 |
| Delivery method: | Transfection |
| Article title: | Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin |
| Authors: | Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith LM, Jain M, Batra SK |
| Journal Reference: | Br J Cancer. 2011 Mar 15;104(6):1038-48. doi: 10.1038/bjc.2011.31. Epub 2011 Mar 1 |
